share_log

名創優品:翌日披露報表

MNSO: Next Day Disclosure Return

香港交易所 ·  Feb 1 04:47
Summary by Moomoo AI
名創優品於2024年2月1日向香港聯合交易所有限公司提交了翌日披露報表,披露其股份購回情況。該公司在2023年12月8日至2024年1月31日期間,透過多次交易購回了總計2,248,600股普通股,佔其已發行股份的0.177939%。最近一次購回發生在2024年2月1日,當日購回175,000股,每股價格介於HKD 33.7至HKD 34之間,總支付金額為HKD 5,927,100。名創優品確認,所有購回活動均按照香港及美國的相關規則進行,並且已獲得董事會的正式授權批准。
名創優品於2024年2月1日向香港聯合交易所有限公司提交了翌日披露報表,披露其股份購回情況。該公司在2023年12月8日至2024年1月31日期間,透過多次交易購回了總計2,248,600股普通股,佔其已發行股份的0.177939%。最近一次購回發生在2024年2月1日,當日購回175,000股,每股價格介於HKD 33.7至HKD 34之間,總支付金額為HKD 5,927,100。名創優品確認,所有購回活動均按照香港及美國的相關規則進行,並且已獲得董事會的正式授權批准。
MIGUO PREMIUM FILED A NEXT DAY DISCLOSURE REPORT WITH THE HONG KONG UNITED EXCHANGE LIMITED ON FEBRUARY 1, 2024, DISCLOSING THE REPURCHASE OF ITS SHARES. Between December 8, 2023 and January 31, 2024, the Company repurchased a total of 2,248,600 shares of ordinary shares, representing 0.177939% of its issued shares, through multiple transactions. The most recent repurchase took place on February 1, 2024, and repurchased 175,000 shares at a price of HKD 33.7 to HKD 34 for a total payment of HKD 5,927,100. NAZU confirms that all repurchases are conducted in accordance with the relevant rules in Hong Kong and the United States and have been formally authorized by the Board of Directors.
MIGUO PREMIUM FILED A NEXT DAY DISCLOSURE REPORT WITH THE HONG KONG UNITED EXCHANGE LIMITED ON FEBRUARY 1, 2024, DISCLOSING THE REPURCHASE OF ITS SHARES. Between December 8, 2023 and January 31, 2024, the Company repurchased a total of 2,248,600 shares of ordinary shares, representing 0.177939% of its issued shares, through multiple transactions. The most recent repurchase took place on February 1, 2024, and repurchased 175,000 shares at a price of HKD 33.7 to HKD 34 for a total payment of HKD 5,927,100. NAZU confirms that all repurchases are conducted in accordance with the relevant rules in Hong Kong and the United States and have been formally authorized by the Board of Directors.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more